Plain Language Summary {#S0001}
======================

Treatment of chronic obstructive lung disease (COPD) in line with the recommendations of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline has been shown to improve the patient's quality of life and to decrease healthcare costs. However, the compliance of prescribed pharmacotherapy to GOLD guidelines appears to be suboptimal, according to cross-sectional studies. We evaluated the conformity of pharmacotherapy with GOLD guidelines in a longitudinal study, investigating a Swiss cohort of patients with COPD. We found the pharmacotherapy regimens in our cohort to be only partially compliant with guidelines, most commonly due to overtreatment with inhaled corticosteroids, but also overtreatment with or a lack of bronchodilator-treatment was observed frequently. Furthermore, longitudinal changes in therapy-regimens that would had been necessary according to GOLD guidelines were rarely implemented correctly. We, therefore, conclude that the guideline-conformity of COPD treatment yet leaves considerable room for improvement, in order to achieve optimal symptom reduction in each patient.

Introduction {#S0002}
============

Chronic obstructive pulmonary disease (COPD), with a global prevalence of approximately 11.7%, is considered the fourth leading cause of death worldwide.[@CIT0001],[@CIT0002] COPD is associated with a significant economic burden, producing annual costs of nearly 50 billion Euros in the European Union.[@CIT0003] The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy-guideline aims for the inclusion of concurrent therapy recommendations in clinical practice. Optimal pharmacological treatment of patients with COPD can improve symptoms,[@CIT0004]--[@CIT0007] exercise capacity,[@CIT0004],[@CIT0006] health status,[@CIT0008] and reduces exacerbations.[@CIT0009],[@CIT0010] Accordingly, optimal implementation of GOLD-guidelines in clinical practice has been shown to significantly decrease healthcare costs.[@CIT0011] Whereas a lack in pharmacotherapy might impair patient and healthcare outcomes, overtreatment should be avoided as well. Especially indications for inhaled corticosteroids (ICS) have become fewer, due to their unfavourable cost-benefit-ratio, with regards to serious adverse events and the superior effectiveness of long-acting bronchodilators (BD) in decreasing exacerbations.[@CIT0012] Despite the beneficial outcomes associated with guideline-complying therapy, various cross-sectional studies showed GOLD-implementation to be suboptimal, presumably due to poor familiarity of physicians with guidelines.[@CIT0013]--[@CIT0015] Additionally, substantial changes in GOLD reports published throughout the years, such as the introduction and modification of the »ABCD«-scheme in 2011 and 2017, possibly impair clinician's familiarity with the recommendations even more. Yet, due to the progressive nature of COPD, treatment regimens have to be re-evaluated at least annually.[@CIT0016] However, knowledge of the clinical realisation of recommended therapy adjustments in longitudinal settings is mostly lacking.

The aim of this study was to evaluate the clinical implementation of recommendations for pharmacotherapy and pharmacotherapy-adjustments based on GOLD-guidelines, in a Swiss cohort of patients with mild-to-very-severe COPD.

Methods {#S0003}
=======

Subjects {#S0003-S2001}
--------

This is a sub-analysis of the prospective, non-interventional cohort study \'The Obstructive Pulmonary Disease Outcomes Cohort Study (TOPDOCS)\'. Patients with COPD from seven pulmonary outpatient clinics in Switzerland were included in the cohort during outpatient visits or hospital stays. Follow-up visits took place annually for up to 7 years, from October 2010 until December 2016, within a mean follow-up period of 2.03 years. Patients with confirmed mild-to-very-severe COPD were eligible. Exclusion criteria were mental constraint disabling the patient to give written informed consent and to comply with the study instructions, respectively. The Ethics Committee of Zurich approved the study (EK-ZH-NR: 1734 and 2011--0106), which was conducted in accordance with the declaration of Helsinki and which was registered at [[www.ClinicalTrials.gov](http://www.ClinicalTrials.gov)]{.ul}, NCT01527773.

Measurements {#S0003-S2002}
------------

The following factors were assessed annually.

### Comorbidities, Symptoms and Health Status {#S0003-S2002-S3001}

Interviews, clinical examinations, and reviews of the medical history were performed. COPD-associated symptoms and their impact on health were evaluated by means of COPD Assessment testing (CAT).[@CIT0017] The severity of dyspnoea was assessed with the help of the modified medical research council (mMRC) scale.[@CIT0018] Acute exacerbations (AE) were defined as an increase in dyspnoea, cough and/or sputum production, requiring treatment with antibiotics and/or oral corticosteroids. Participants were classified as frequent exacerbators when at least two-, and as infrequent exacerbators when less exacerbations occurred during the respective previous year.

### Respiratory Variables {#S0003-S2002-S3002}

Forced expiratory volume in one second (FEV1), residual volume to total lung capacity (RV/TLC), and diffusing capacity of the lung for carbon monoxide (DLco) were measured after bronchodilation within a standard pulmonary functioning test, performed in accordance with guidelines of the American Thoracic Society and the European Respiratory Society.[@CIT0019],[@CIT0020] Participants were categorised into GOLD stages (I--IV), and risk groups (A-D) consistent with the respective concurrent guideline at each visit.[@CIT0012],[@CIT0021],[@CIT0022]

### Medication and Accordance with Guidelines {#S0003-S2002-S3003}

For each visit, we evaluated the conformity of prescribed pharmacotherapy with the respective, concurrently valid GOLD guideline. The study started in 2010; thus, the valid guideline for the 2010 visits was the 2006 GOLD report. Within the course of the trial, changes in guidelines with an impact on treatment recommendations were published in the 2011 revision and the 2014 update.[@CIT0021],[@CIT0022] Identifying overtreatment in line with the GOLD recommendation-table is quite distinct (figure 5.3--7 in guideline 2007, figure 4.4 in guidelines 2011 and 2014).[@CIT0012],[@CIT0021],[@CIT0022] For instance, patients in risk-group A or B receiving ICS are clearly overtreated. However, more careful considerations are required when defining undertreatment, as, for example, GOLD A patients who do not receive medical treatment are not necessarily undertreated. According to GOLD, a lack of bronchodilator (BD) treatment is only present when the patient receives no such drug despite being symptomatic. Therefore, only symptomatic patients (mMRC-score≥2 or CAT-score≥10) who did not receive an inhaled BD were classified undertreated. The 2006 report recommends adding ICS in patients with GOLD stage III and IV, who have repeated exacerbations; thus, these criteria were adopted for defining ICS undertreatment in visits before 2011. In line with GOLD 2011 and 2014, from 2011 on, patients not receiving ICS were defined as ICS undertreated when they were categorised GOLD stage III or IV and had exacerbations frequently (≥2 per year), despite treatment with long-acting BDs. The absence of roflumilast was not rated as undertreatment, since the recommendation for this agent is rather weak. GOLD-2011 and 2014 state that it may be added in stage III or IV patients with frequent exacerbations that are not adequately controlled by long-acting BDs. However, roflumilast prescribed to patients with GOLD stage I or II was defined as overtreatment from 2011 on.

### Changes in Recommended Medication Over Time and Influence of Guideline Changes {#S0003-S2002-S3004}

We investigated whether step-ups or step-downs in GOLD stage or risk-group were accompanied by adequate changes in prescribed medication. Furthermore, we longitudinally analysed individual changes in therapy-recommendations, which were conditioned exclusively by guideline change. Therefore, whenever a step-up or -down in risk-group was noticed in a visit following a change in the guideline, the respective recommendation was compared to what would have been recommended in the former guideline, for the specific case. Furthermore, we applied the categorisation criteria from GOLD 2017 on our cohort for investigating the impact of this guideline on individual treatment-suggestions. In the 2017 GOLD report, the »ABCD«-system was significantly modified, as airway obstruction was excluded from the categorisation criteria.

### Statistical Analysis {#S0003-S2002-S3005}

Descriptive statistics include mean and standard deviation (SD) for normally distributed parameters, as well as median and 25%/75%-quartiles for non-normally distributed variables. Categorical variables are shown as numbers and percentages of the total. For continuous variables, groups (correct treatment vs undertreatment vs overtreatment vs varying treatment) were compared via ANOVA. For post-hoc testing, one-way ANOVA was used. P-values were Bonferroni corrected. Categorical variables were assessed by Chi-squared test. A two-sided p-value of \<0.05 was considered to be statistically significant. We used STATA/SE15.1 (StataCorp, College Station, TX, USA) for analysis.

Results {#S0004}
=======

Participants {#S0004-S2001}
------------

Three hundred and twenty-six patients initially gave consent and data of 305 participants (726 study-visits) were available for analysis ([Figure 1](#F0001){ref-type="fig"}). See [Table 1](#T0001){ref-type="table"} for baseline characteristics.Table 1Baseline CharacteristicsClinical CharacteristicsAge, years62.3 (7.3)Male, n/total (%)201/305 (65.90%)BMI, kg/m^2^26 (22.5/29.4)Smoker, n/total (%)231/305 (75.74%)Pack years, n40 (30/60)GOLD stage 1, n/total (%)26/305 (8.52%)GOLD stage 2, n/total (%)100/305 (32.79%)GOLD stage 3, n/total (%)111/305 (36.39%)GOLD stage 4, n/total (%)68/305 (22.30%)mMRC-Score, n1.73 (1.06)CAT-Score, n16 (7.24)FEV1 post dilatation, % predicted44 (31/64.2)RV/TLC, % predicted55.27 (11.84)DL~CO~ (Hb), % predicted47 (35/68)Exacerbations in previous year, n1 (0/2)Exacerbations in previous year leading to hospitalisation, n0 (0/0)Frequent exacerbator, n/total (%)77/305 (25.25%)[^1][^2] Figure 1Study flow. The decrease in the number of participants has several reasons: the cohort-study was initially designed as a cross-sectional trial. During the course of the first year, the design was changed to a longitudinal study intended to analyse the course of lung function, exacerbations, cardiovascular outcomes, and further parameters over a period of 3 years. The participants gave consent to only one study visit initially and, when asked again after the first year, a great number of participants did not agree to taking part in a 3-year-study. Then again, after 3 years, the study period was extended and only a part of the participants agreed to continue. Additionally, parts of the initial COPD-cohort had died within the study period.

Implementation of GOLD Recommendations {#S0004-S2002}
--------------------------------------

A 8.8% of visits fell under the scope of the 2006, 54.3% of the 2011, and 36.9% of the 2014 GOLD-guidelines. In 59.1% of visits, the prescribed medication conformed to the concurrent recommendations, 61.8% and 59.0% before and after the introduction of risk-groups in 2011, respectively. GOLD non-compliant therapy was due to overtreatment with ICS in 40.7%, with long-acting BD in 9.8%, with ICS and long-acting BD in 1.5%, and due to undertreatment with ICS, BD, or ICS and long-acting BD, in 17.1%, 16.7%, and 1.5% of cases, respectively. The distribution of pharmacotherapies and the accordance with GOLD-guidelines are shown before and after the introduction of symptom-based categories in 2011 ([Tables 2](#T0002){ref-type="table"} and [3](#T0003){ref-type="table"}, [Figure 2A](#F0002){ref-type="fig"} and [B](#F0002){ref-type="fig"}).Table 2Overview on Medication of the Cohort, and Accordance with 2006 GOLD Guideline (Visits That Took Place Before 2011)GOLD StageIIIIIIIV**Prescribed medication of cohort**No treatment57.1%52.9%4.8%0.0%LAMA28.6%5.9%4.8%5.0%LAMA+ICS0.0%0.0%4.8%5.0%LABA+ICS14.3%17.6%4.8%5.0%LAMA+LABA0.0%0.0%4.8%5.0%LAMA+LABA+ICS0.0%23.5%66.7%70.0%LABA+ICS+THEO0.0%0.0%4.8%5.0%LAMA+LABA+ICS+THEO0.0%0.0%4.8%5.0%% of total visits10.8%26.2%32.3%30.8%**Accordance with GOLD 2006**% treatment according to guideline25%33.3%78.6%85.7%**Undertreatment**Short-acting BD25%0.0%0.0%0.0%Short and long-acting BD0.0%33.3%0.0%0.0%ICS0.0%0.0%0.0%14.3%**Overtreatment**Long-acting BD50%0.0%0.0%0.0%ICS0.0%22.2%21.4%0.0%Long-acting BD and ICS0.0%11.1%0.0%0.0%[^3][^4] Table 3Overview on Medication of the Cohort, and Accordance with GOLD 2011/2014 (Visits from 2011 on)Risk GroupABCD**Prescribed medication of cohort**No treatment43.8%29.2%3.8%2.3%SABA6.9%1.2%1.7%0.3%LAMA11.5%17.6%5.1%2.8%LAMA+ICS0.0%0.0%0.0%1.2%LABA3.8%4.7%1.7%0.6%LABA+ICS13.1%15.9%15.3%9.8%LAMA+LABA6.2%5.9%16.9%8.3%LAMA+LABA+ICS13.8%28.2%45.8%63.5%LAMA+ICS+ROFL0.0%0.0%0.0%0.6%LAMA+LABA+ROFL0.0%0.6%0.0%0.6%LAMA+LABA+ICS+ROFL0.8%2.4%3.4%9.2%LABA+ICS+THEO0.0%0.6%0.0%0.6%LAMA+LABA+THEO0.0%0.0%0.0%0.3%LAMA+LABA+ICS+THEO0.0%0.6%1.7%1.2%% of total visits19%24.8%8.6%47.6%**Accordance with GOLD 2011/14**%treatment according to guideline65.9%30.0%38.6%76.1%**Undertreatment**BD0.0%22.4%0.0%0.0%ICS0.0%0.0%14.0%11.7%Long-acting BD and ICS0.0%0.0%0.0%1.2%**Overtreatment**Long-acting BD9.4%0.0%28.1%0.0%GC20.0%45.3%5.3%0.0%Long-acting BD and ICS3.5%0.0%0.0%0.0%ROFL0.0%0.6%0.0%0.0%Overtreatment, categories not applicable1.2%1.8%14.0%9.8%**Other**Incorrect treatment, over or undertreatment not applicable0.0%0.0%0.0%0.6%[^5][^6] Figure 2Distribution of prescribed medication and accordance with guidelines. (**A**) By risk-category: distribution of prescribed medicine. Nineteen percent of participants were categorised group A, 24.8% B, 8.6% C, and 47.6% D. Visits, in which the patient had no medication were not depicted in (**A**) due to clarity reasons. (**B**) By GOLD-stage (visits before 2011), or risk-category (visits from 2011 on): amount of visits where correct treatment, undertreatment, and overtreatment was observed. In visits before 2011, 12% of patients were GOLD-stage 1, 26% stage 2, 41% stage 3, and 21% stage 4. In visits from 2011 on, 19% of participants were categorised group A, 24.8% B, 8.6% C, and 47.6% D.**Abbreviations:** SABA, short-acting β2-receptor agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; LABA, long-acting β2-receptor agonist; ROFL, Roflumilast; THEO, Theophylline; BD, Bronchodilator.

Adjustments of Treatment Regimens to Worsening of COPD and Guideline-Change {#S0004-S2003}
---------------------------------------------------------------------------

Step-ups and -downs in risk-category requiring escalation, or de-escalation of pharmacotherapy were noticed in 24, and 43 follow-up visits, respectively. Steps-ups were adequately implemented in 4 (16.7%), steps down in 6 cases (14.0%), after a mean period of 1.1 visits. Participants whose therapy was adjusted in line with recommendations were categorised risk-group A in 30%, B in 20%, C in 10%, and D in 40%. Cases in which adequate therapy-adjustments were missed out were followed for 1.6 visits in mean. None of the observed steps occurred exclusively due to a change in the guideline. However, when categorising our cohort after the GOLD-2017-criteria, 44.20% of participants would be shifted from group D to B, and 6.2% from group C to A or B.

Comparison of Characteristics Between Groups {#S0004-S2004}
--------------------------------------------

A comparison of characteristics between participants who were correctly-, under-, over-, or variably treated throughout all visits can be seen in [Table 4](#T0004){ref-type="table"}. The group of steadily undertreated participants had a significantly higher body-mass-index (BMI), and contained the largest amount of smokers, when compared with the rest of the cohort. Compliantly treated participants had the significantly highest mMRC and CAT scores, lowest FEV1 and DLco and highest RV/TLC values of all groups. Among under- and overtreated participants, there were significantly less frequent exacerbators, when compared with the correctly treated patients.Table 4Comparison of Clinical Characteristics Between GroupsBaseline (N=306)Correct Treatment N=161Undertreatment N=35Overtreatment N=35Varying Treatment N=74Overall p-valueMedian age, years64 (58/69)62 (54/68.5)63 (52.67/68)65.5 (61.5/70)**0.017**Median body-mass-index, kg/m^2^24.2 (21.03/28.37)28.6 (25.11/33.89)\*26.53 (23.2/28.72)^†^26.035 (22.9/28.9)^†^**\<0.001**Female/male sex (%female)57/104 (35.40%)6/29 (17.14)14/21 (40.00%)27/47(36.49%)**0.149**Non-smoker/smoker at baseline (%non-smoker)130/31 (80.75%)19/16\* (54.29%)25/10 (71.43%)57/17^†^ (77.03%)**0.010**Median mMRC-score, n2 (1.5/3)0 (1/1.5)\*1 (0.5/2)\*1 (1/2)\***\<0.001**Median CAT-score, n18 (14/22)12 (7/14.5)\*13 (7/19)\*13 (9/20)\***\<0.001**Median FEV1 post dilation, % predicted34 (25/43.5)73 (55/82)\*61 (43/74)\*55.5 (43/69)\*^†^**\<0.001**Median RV/TLC, %62 (54/68)42.75 (37/49)\*49 (41/58)\*51.87 (46/59.5)\*^†^**\<0.001**Median DLco, mmol/kPa/min36 (29/50)72.5 (59/83.5)\*53 (38/69)\*^†^56.5 (41.5/71)\*^‡^**\<0.001**Frequent exacerbator at baseline, no/yes (%no)109/52 (67.70%)33/2\* (94.29%)31/4\* (88.57%)55/19^†^ (74.32%)**0.002**[^7][^8]

Discussion {#S0005}
==========

This study evaluated the conformity of COPD-pharmacotherapy and therapy adjustments, with GOLD guidelines. To our knowledge, no previous trial classified under- and overtreatment-categories in this detail. We found that the prescribed medications were only partially compliant with guidelines. Furthermore, required escalations and de-escalations of pharmacotherapy were inadequately realised. Patients with more severe COPD were more likely to be treated in accordance with guidelines.

Whereas COPD is not curable, it is yet a treatable condition. Pharmacological treatment is a fundamental component of COPD therapy, as it has been shown to improve the patient's quality of life,[@CIT0023] when administered in accordance with treatment recommendations. However, previous studies suggested discrepancies between prescribed medication and guideline-propositions. The rather low rate of guideline-adherent therapy prescribed in our cohort (59.1%) is in line with the results of earlier studies.[@CIT0014],[@CIT0024] Factors that might explain the low conformity-rates, next to inadequate familiarity with guidelines, might be time-constraints or low self-efficacy of physicians.[@CIT0025] Educational interventions to improve physician's familiarity with guidelines have been shown to be successful; thus, their utilisation should be further promoted.[@CIT0025],[@CIT0026] In this study, ICS over-prescription was the most common reason for guideline non-compliance. This finding is quite alarming, as serious side-effects of ICS, such as pneumonia, could be avoided.[@CIT0027] Especially in combination with long-acting muscarinic antagonists (LAMA) and long-acting β2-receptor agonists (LABA), ICS over-prescription was observed in other populations with COPD as well.[@CIT0014],[@CIT0028] Inhaled BDs are effective in reducing dyspnoea and exacerbations, and they show a comparably favourable tolerability over ICS. However, particularly cardiac arrhythmia and tremor are adverse effects that have to be taken into account when prescribing inhaled BDs without impeccable indications. Nevertheless, we also found large amounts of patients that were BD-undertreated. Due to their alleviating effects on dyspnoea and their potential to reduce exacerbations, treatment with BDs is of central importance in COPD.[@CIT0016],[@CIT0029] Yet, with regard to our results, the rate of patients treated with inhaled BDs is improvable.

Required escalations, or de-escalations in pharmacotherapy were rarely implemented correctly within our cohort. This finding calls into question the physician's familiarity with guidelines and their routine in classifying disease severity and establishing treatment regimens. In a survey reported by Palmiotti et al,[@CIT0014] 60% of pulmonologists stated that the categorisation into the »ABCD«-groups was cumbersome in clinical practice, as performing spirometry at each visit would take too long. However, the conformity of prescribed medication with guidelines was similar before and after the introduction of the »ABCD«-system in our cohort. Further changes in GOLD-guidelines that were published within our follow-up period had no effects on the individual treatment recommendations of our cohort. Nevertheless, fundamental changes in patient categorisation were published in the 2017 GOLD report, where disease-severity assessed by spirometry was excluded from the »ABCD«-classification-criteria. In line with the results of Cabrera López et al,[@CIT0030] the majority of participants in our study would have been shifted into other groups with application of the GOLD 2017-system, mostly from groups C to A or B, and group D to B. This re-classification causes even greater amounts of patients to be overtreated with ICS. In connection with the low rates of correctly performed therapy adjustments noticed in our cohort, this result suggests that great amounts of patients are still ICS overtreated in 2019. However, whether ICS therapy should be discontinued in these patients is currently under discussion, since ICS withdrawal might be associated with increases in symptoms and exacerbations.[@CIT0016]

We observed that patients who were undertreated throughout all study-visits, had the significantly highest BMI, when compared with the rest of the cohort. We assume that in more obese patients, COPD-severity is likely to be underrated, as overweight itself is a prevalent cause of dyspnoea and wheezing.[@CIT0031] Thus, physicians might underestimate the actual need for COPD-treatment in obese patients. The comparably large amount of smokers within the undertreated group may be a result of these patients\' lower therapy motivations. Besides that, the physician in charge might prompt patients to stop smoking before further escalating pharmacotherapy. Participants treated in compliance with guidelines were most likely to have worse symptom-scores, lung function parameters, and frequent exacerbations. Furthermore, group D-patients were most likely to be treated guideline-compliantly in our study. Accordingly, in a COPD-cohort in Hong Kong, correctly treated patients had more exacerbations when compared with under- and overtreated groups.[@CIT0024] We, therefore, presume that firstly, due to their increased symptoms and exacerbations, patients with more severe COPD have a higher probability to be treated in hospitals, and therefore by specialists. Secondly, these patients experience more disease burden, and therefore might put more effort into their own therapy. Lastly, GOLD-guidelines offer the greatest amount of combinations for medical therapy in risk-group D, thereby increasing the chance to administer a correct treatment.

A limitation of our study is that we did not collect data on the respective physician in charge. Secondly, since the termination of the investigated follow-up-period, important changes in GOLD-guidelines have been published. Nevertheless, our main outcome was the guideline-conformity of therapy-adjustments, which presumably has not changed since 2016. Thirdly, we cannot be sure if every participant had seen the respective physician in charge once yearly, even if yearly follow-up is recommended in GOLD-guidelines. Fourthly, the medication prescribed is not necessarily identical to the medication the patient actually is on. However, information on the respective pharmacotherapy regimen of the individual participants was acquired by asking the patients for the medication they concurrently take. Lastly, we did not ask the respective physicians in charge whether they followed GOLD or other guidelines. Yet, our main outcome was to investigate the accordance of COPD-pharmacotherapy in Switzerland with the international state-of-the-art, rather than the ability of the respective physicians in charge to implement the guidelines they intended to follow.

Conclusions {#S0006}
===========

In conclusion, we found only partial compliance of COPD-pharmacotherapy with GOLD-guidelines. Overtreatment with ICS appears to be the most common therapeutic error, and it is an increased issue nowadays, as indications for ICS have become fewer. However, also undertreatment due to absence of inhaled BDs was frequently noticed in our cohort. As BDs depict the backbone of COPD treatment, enhancing the supply with these agents should be focused. The poor guideline-conformity of treatment-adjustments suggests that the familiarity of physicians with guidelines is insufficient and leaves room for improvement. Particularly pharmacotherapy of patients in lower GOLD stages seems to be suboptimal and thus requires more attention.
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[^1]: **Notes:** Values are presented as Mean (SD) or Median (IQR), unless stated otherwise.

[^2]: **Abbreviations:** BMI, Body Mass Index; GOLD, Global Initiative for Obstructive Lung Disease; mMRC, Modified British Medical Research Council; CAT, Chronic Obstructive Pulmonary Disease Assessment Test; FEV1, Forced expiratory volume in 1 second; RV/TLC, Residual volume/total lung capacity; DL~CO~ (Hb), Carbon monoxide diffusion capacity for haemoglobin concentration.

[^3]: **Notes:** Values are presented as percentage of the respective stage of disease, separately for the prescribed medicine, and the accordance with guidelines, respectively.

[^4]: **Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; SABA, short-acting β2-receptor agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; LABA, long-acting β2-receptor agonist; ROFL, Roflumilast; THEO, Theophylline; BD, Bronchodilator.

[^5]: **Notes:** Values are presented as percentage of the respective stage of the disease, separately for the prescribed medicine, and the accordance with guidelines, respectively.

[^6]: **Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; SABA, short-acting β2-receptor agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; LABA, long-acting β2-receptor agonist; ROFL, Roflumilast; THEO, Theophylline; BD, Bronchodilator.

[^7]: **Notes:** \*p\<0.05 vs "correct treatment"; ^†^p\<0.05 vs "undertreatment", ^‡^p\<0.05 vs "overtreatment". Variables are presented as mean (SD) or Median (IQR) unless otherwise stated.

[^8]: **Abbreviations:** mMRC, Modified British Medical Research Council; CAT, chronic obstructive pulmonary disease Assessment Test; FEV1, Forced Expiratory Volume; RV, Residual Volume; TLC, Total Lung Capacity; DLco, Diffusion factor of the Lung for Carbon Monoxide.
